Phase 2b Trial of Psoriasis Therapy Prurisol Reaches 70% of Participant Target
An already started Phase 2b clinical trial of Prurisol as a treatment for moderate-to-severe chronic plaque psoriasis has recruited more than 70 percent of the 189 participants that researchers hoped for.
The therapy’s developer, Cellceutix Corporation, said it expects to release the trial’s initial results during the third quarter of 2017.
Prurisol is an oral immunomodulatory therapy that reduces the expression of an RNA molecule called PRINS whose function has yet to be determined. PRINS stands for Psoriasis susceptibility-related RNA Gene Induced by Stress. Expression is the process by which information from a gene is used to create a functional product like a protein.
Cellceutix is following a regulatory path that it hopes can accelerate Prurisol’s U.S. approval. The Federal Drug Administration allows a company to use long-term safety results of an approved drug that is similar to its own when it seeks its candidate’s approval. In this case, the drug is a Prurisol bioequivalent called Ziagen.